Detection of Myocardial Damage in Patients With Sarcoidosis

Manesh R. Patel, MD; Peter J. Cawley, MD; John F. Heitner, MD; Igor Klem, MD; Michele A. Parker, MS; Wael A. Jaroudi, MD; Trip J. Meine, MD; James B. White, MD; Michael D. Elliott, MD; Han W. Kim, MD; Robert M. Judd, PhD; Raymond J. Kim, MD

Background—In patients with sarcoidosis, sudden death is a leading cause of mortality, which may represent unrecognized cardiac involvement. Delayed-enhancement cardiovascular magnetic resonance (DE-CMR) can detect minute amounts of myocardial damage. We sought to compare DE-CMR with standard clinical evaluation for the identification of cardiac involvement.

Methods and Results—Eighty-one consecutive patients with biopsy-proven extracardiac sarcoidosis were prospectively recruited for a parallel and masked comparison of cardiac involvement between (1) DE-CMR and (2) standard clinical evaluation with the use of consensus criteria (modified Japanese Ministry of Health [JMH] guidelines). Standard evaluation included 12-lead ECG and at least 1 dedicated non-CMR cardiac study (echocardiography, radionuclide scintigraphy, or cardiac catheterization). Patients were followed for 21±8 months for major adverse events (death, defibrillator shock, or pacemaker requirement). Patients were predominantly middle-aged (46±11 years), female (62%), and black (73%) and had chronic sarcoidosis (median, 7 years) and preserved left ventricular ejection fraction (median, 56%). DE-CMR identified cardiac involvement in 21 patients (26%) and JMH criteria in 10 (12%, 8 overlapping), a 2-fold higher rate for DE-CMR (P=0.005). All patients with myocardial damage on DE-CMR had coronary disease excluded by x-ray angiography. Pathology evaluation in 15 patients (19%) identified 4 with cardiac sarcoidosis; all 4 were positive by DE-CMR, whereas 2 were JMH positive. On follow-up, 8 had adverse events, including 5 cardiac deaths. Patients with myocardial damage on DE-CMR had a 9-fold higher rate of adverse events and an 11.5-fold higher rate of cardiac death than patients without damage.

Conclusions—In patients with sarcoidosis, DE-CMR is more than twice as sensitive for cardiac involvement as current consensus criteria. Myocardial damage detected by DE-CMR appears to be associated with future adverse events including cardiac death, but events were few, and this needs confirmation in a larger cohort. (Circulation. 2009;120:1969-1977.)

Key Words: cardiomyopathy ■ sarcoidosis ■ magnetic resonance imaging

Cardiac involvement is clinically evident in only 5% of patients with sarcoidosis,1 yet myocardial lesions are found at autopsy in 20% to 60%.2-4 Importantly, sudden death is the leading cause of mortality in patients with sarcoidosis in Japan and perhaps the second most common after pulmonary complications in the United States.4,5 Therefore, it has been postulated that cardiac involvement in patients with sarcoidosis is often clinically unrecognized and is a primary cause of death.6

Clinical Perspective on p 1977

Antemortem recognition of cardiac sarcoidosis may be difficult in part because of the lack of a sensitive diagnostic method. Although a positive endomyocardial biopsy may be specific for cardiac involvement, the diagnostic yield is low even in patients with signs and symptoms consistent with cardiac sarcoidosis, presumably because of the patchy nature of the disease.7 Consensus criteria for the diagnosis of cardiac sarcoidosis have been developed by the Japanese Ministry of Health and Welfare (JMH).8 These criteria involve multiple diagnostic tests, including an ECG and a dedicated cardiac imaging study (echocardiogram, radionuclide scintigraphy, or cardiac catheterization), and provide guidance for identifying cardiac involvement when endomyocardial biopsy either is not performed or is nondiagnostic. In general, the imaging studies are used to identify ventricular dilatation, abnormal function, or perfusion defects. However, a large amount of myocardial damage may be required before these are evident.9,10

Delayed-enhancement cardiac magnetic resonance (DE-CMR) with the use of gadolinium contrast is a relatively recent technique that allows visualization of even minute amounts of myocardial damage.11,12 We hypothesized that in patients with sarcoidosis, DE-CMR would be more sensitive

Received January 14, 2009; accepted September 9, 2009.
© 2009 American Heart Association, Inc.
Circulation is available at http://circ.ahajournals.org DOI: 10.1161/CIRCULATIONAHA.109.851352

1969
at detecting cardiac involvement than standard clinical evaluation with the use of consensus criteria. Additionally, to assess the prognostic significance of myocardial damage identified by DE-CMR, all patients were followed for adverse clinical events.

**Methods**

**Population and Protocol**

From September 2002 through December 2004, we approached pulmonary, rheumatology, and general medicine physicians whose clinical practices included patients with sarcoidosis. We evaluated consecutive patients referred from these practices for possible inclusion in the study. The primary criterion for enrollment was the presence of biopsy-proven extracardiac sarcoidosis. We excluded patients in whom the diagnosis of cardiac sarcoidosis had already been given because we wished to compare strategies for obtaining this diagnosis prospectively. Other exclusion criteria included prior myocardial infarction or known coronary disease, which could potentially confound both DE-CMR and consensus criteria interpretations, and standard CMR contraindications (Figure 1A). All patients gave informed written consent for the protocol, which was approved by the Duke institutional review board.

The study protocol involved 4 distinct steps after enrollment (Figure 1A). The first was the collection of a complete medical history from each patient, which included demographic information, site of tissue diagnosis for sarcoidosis, organs involved, years since diagnosis, and medication treatment history. The second was a parallel assessment for cardiac involvement. Patients underwent both a standard clinical evaluation applying modified JMH guidelines (Figure 1B) and a CMR study. The third was masked determination of cardiac involvement by modified JMH criteria and the analysis of DE-CMR. The fourth step involved clinical follow-up to track major adverse events and the availability of cardiac tissue from either endomyocardial biopsy or autopsy to validate imaging findings.
Standard Clinical Evaluation
In the absence of histological evidence of cardiac sarcoidosis, the JMH criteria require a combination of an ECG abnormality and evidence of ventricular dilatation, dysfunction, or perfusion defects on either echocardiography, radionuclide scintigraphy, or cardiac catheterization (Figure 1B). Therefore, all patients underwent 12-lead ECG and at least 1 dedicated cardiac imaging study (non-CMR). All ECG and imaging data were reviewed blinded to clinical history and CMR findings.

Endomyocardial biopsy was performed at the discretion of the treating physician and patient after enrollment and was not mandated. Similar to previous studies,13 JMH criteria were modified by excluding endomyocardial biopsy as a diagnostic parameter because not all patients underwent biopsy. However, all cardiac tissue obtained during follow-up from endomyocardial biopsy or autopsy was evaluated in a systematic manner (see Pathology Validation section). X-ray coronary angiography was also performed at the discretion of the treating physician, but, in general, patients with abnormalities on noninvasive cardiac imaging (non-CMR or CMR) underwent angiography to exclude obstructive coronary disease (defined as >50% narrowing of the luminal diameter of at least 1 major epicardial artery14).

Cardiovascular Magnetic Resonance
Acquisition
Images were acquired on a 1.5-T scanner (Siemens Sonata) with the use of a phased-array coil during repeated breath-holds. Steady-state free-precession cine images were acquired in multiple short-axis (every 10 mm throughout the entire left ventricle [LV]) and long-axis planes for assessment of LV function. Typical parameters were as follows: repetition time, 3.0 ms; echo time, 1.5 ms; flip angle, 60°; temporal resolution, 35 ms; in-plane resolution, 1.7 × 1.4 mm. Standard delayed-enhancement images were acquired with the use of a segmented inversion-recovery gradient-echo sequence (in-plane resolution, 1.8 × 1.4 mm; temporal resolution, 160 to 200 ms) 10 minutes after contrast administration (gadoversetamide, 0.15 mmol/kg) in planes identical to those of cine imaging (both, slice thickness of 6 mm, gap of 4 mm).15 Inversion delay times were typically 280 to 360 ms, and total time for the CMR evaluation was ~30 minutes.

Analysis
Scans were placed in random order and analyzed masked to all clinical information, including JMH status. Cine and DE-CMR images were evaluated separately. LV ejection fraction (LVEF) and LV volumes were measured quantitatively on the basis of end-diastolic and end-systolic endocardial contours from the stack of short-axis cine images.16 The presence, location, and extent of hyperenhanced tissue, which was assumed to represent scarred, damaged myocardium,16 were determined by the consensus of 2 observers using a standard 17-segment LV model and a 5-point scale for each segment (0=no hyperenhancement; 1=1% to 25% area hyperenhanced; 2=26% to 50%; 3=51% to 75%; and 4=76% to 100%).17,18 Global hyperenhancement volume as a percentage of LV myocardium was calculated by summing the segments with hyperenhancement (each weighted by the midpoint of the range of hyperenhancement for the given segmental score [ie, 1=13%; 2=38%; 3=63%; 4=88%]) and dividing by 17,17,18. Additionally, the pattern of hyperenhancement was classified as either coronary artery disease (CAD) type or non-CAD type as described previously.19,20 In brief, because ischemic injury progresses as a “wavefront” from the subendocardium to the epicardium,21 hyperenhancement involving the LV subendocardium was considered CAD type. Conversely, hyperenhancement patterns that spared the subendocardium and instead were limited to the middle or epicardial portion of the LV wall were considered non-CAD type. With this classification, nontransmural hyperenhancement of the right ventricular (RV) side of the interventricular septum was considered non-CAD type. The RV free wall was also evaluated for hyperenhancement (classified as non-CAD type); however, given the limited spatial resolution of DE-CMR in comparison to normal RV wall thickness, only the presence or absence of RV hyperenhancement was scored.

Clinical Follow-Up
Clinical information on adverse events was obtained via the following: (1) telephone interview with the patient or, if deceased, with family members; (2) contact with the patient’s physician(s); (3) hospital records; and (4) death certificates. The prespecified primary end point was a composite of all-cause mortality or symptomatic arrhythmia, defined as ventricular tachyarrhythmia leading to appropriate cardioverter-defibrillator discharge (based on stored electrograms) or symptomatic bradyarrhythmia leading to pacemaker implantation. No patient was lost to follow-up. For deceased patients, the cause of death was identified in all cases and classified in accordance with standard criteria.22 The secondary end point was death from cardiac causes alone. All event information was obtained and classified without knowledge of JMH status or CMR findings.

All patients were enrolled before the recent Food and Drug Administration alerts on the rare occurrence of nephrogenic systemic fibrosis associated with gadolinium administration.23 The majority had normal renal function (all had glomerular filtration rate >45 mL/min per 1.73m²), and none developed nephrogenic systemic fibrosis during the follow-up period.

Pathology Validation
During follow-up, all patients who underwent endomyocardial biopsy and/or postmortem autopsy were identified. A cardiovascular pathologist unaware of JMH status and CMR findings examined all cardiac tissue samples. Histological samples were considered positive for cardiac sarcoidosis on the basis of the presence of noncaseating epithelioid granulomas in the absence of organisms or particles that could lead to granuloma formation. The presence and location of myocardial fibrosis/scarring were also noted.

Statistical Analysis
Continuous, normally distributed data were expressed as mean±SD, and between-group comparisons were made with the use of 2-sample t tests. The median and first and third quartiles were used to summarize non–normally distributed, continuous data, and between-group comparisons were made with the use of Wilcoxon tests. Comparisons of discrete variables between groups were made with the use of χ² tests; Fisher exact test was used in those instances in which the expected cell count was <5. The comparison of cardiac involvement by JMH versus DE-CMR was made with the use of the McNemar test. Logistic regression analysis was used to assess the relationship between clinical characteristics (listed in the Table) and the presence of cardiac involvement on DE-CMR. Event-free survival and cardiac survival (time to first event) were plotted as Kaplan–Meier curves. All statistical tests were 2-tailed, and P<0.05 was regarded as significant. S-PLUS (version 8.0, Insightful Software, Seattle, Wash) was used to perform the statistical analyses.

Dr Kim and Dr Patel had full access to and take full responsibility for the integrity of the data. All authors have read and agree to the manuscript as written.

Results
Population
Among 89 consecutive patients referred for possible enrollment into the study, 8 were excluded. Four did not have documentation of biopsy-proven extracardiac sarcoidosis, 2 were found to have a clinical history of prior myocardial infarction, and 2 decided not to participate before CMR. The remaining 81 patients met criteria and were enrolled. The baseline features of the patients are presented in the Table. Patients were predominantly middle-aged (46±11 years), female (62%), and black (73%). The most common extracardiac site with clinical involvement was lung (95%), and >1
### Table. Baseline Characteristics

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Overall (n=81)</th>
<th>DE-CMR+ (n=21)</th>
<th>DE-CMR− (n=60)</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, y</td>
<td>46±11</td>
<td>49±9</td>
<td>45±11</td>
<td>0.11</td>
</tr>
<tr>
<td>Female sex, n (%)</td>
<td>50 (62)</td>
<td>11 (52)</td>
<td>39 (65)</td>
<td>0.31</td>
</tr>
<tr>
<td>Race, n (%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>White</td>
<td>21 (26)</td>
<td>6 (29)</td>
<td>15 (25)</td>
<td>0.80</td>
</tr>
<tr>
<td>Black</td>
<td>59 (73)</td>
<td>15 (71)</td>
<td>44 (73)</td>
<td></td>
</tr>
<tr>
<td>Other</td>
<td>1 (1)</td>
<td>0 (0)</td>
<td>1 (2)</td>
<td></td>
</tr>
<tr>
<td>Extracardiac sarcoidosis, n (%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Positive biopsy site (may be &gt;1)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lung</td>
<td>59 (73)</td>
<td>15 (71)</td>
<td>44 (73)</td>
<td>1.00</td>
</tr>
<tr>
<td>Lymph node</td>
<td>15 (19)</td>
<td>5 (24)</td>
<td>10 (17)</td>
<td>0.52</td>
</tr>
<tr>
<td>Skin</td>
<td>10 (12)</td>
<td>5 (24)</td>
<td>5 (8)</td>
<td>0.12</td>
</tr>
<tr>
<td>Liver</td>
<td>6 (7)</td>
<td>0 (0)</td>
<td>6 (10)</td>
<td>0.19</td>
</tr>
<tr>
<td>Other</td>
<td>8 (10)</td>
<td>1 (5)</td>
<td>7 (12)</td>
<td>0.45</td>
</tr>
<tr>
<td>Clinical organ involvement (may be &gt;1)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lung</td>
<td>77 (95)</td>
<td>20 (85)</td>
<td>57 (95)</td>
<td>1.00</td>
</tr>
<tr>
<td>Skin</td>
<td>17 (21)</td>
<td>7 (33)</td>
<td>10 (17)</td>
<td>0.13</td>
</tr>
<tr>
<td>Liver</td>
<td>13 (16)</td>
<td>2 (10)</td>
<td>11 (18)</td>
<td>0.50</td>
</tr>
<tr>
<td>Eye</td>
<td>8 (10)</td>
<td>1 (5)</td>
<td>7 (12)</td>
<td>0.45</td>
</tr>
<tr>
<td>Other</td>
<td>20 (25)</td>
<td>5 (24)</td>
<td>15 (25)</td>
<td>1.00</td>
</tr>
<tr>
<td>No. of organs involved</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1 site</td>
<td>54 (67)</td>
<td>13 (62)</td>
<td>41 (68)</td>
<td>0.26</td>
</tr>
<tr>
<td>2 sites</td>
<td>18 (22)</td>
<td>7 (33)</td>
<td>11 (18)</td>
<td></td>
</tr>
<tr>
<td>≥3 sites</td>
<td>9 (11)</td>
<td>1 (5)</td>
<td>8 (13)</td>
<td></td>
</tr>
<tr>
<td>Years since diagnosis, median (quartile 1, quartile 3)</td>
<td>7.0 (3.12)</td>
<td>10.0 (3.18)</td>
<td>6.5 (3.11)</td>
<td>0.46</td>
</tr>
<tr>
<td>Medications, n (%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Use at any time since diagnosis</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>No medications</td>
<td>7 (9)</td>
<td>2 (10)</td>
<td>5 (8)</td>
<td>1.00</td>
</tr>
<tr>
<td>Steroid</td>
<td>74 (91)</td>
<td>19 (80)</td>
<td>55 (92)</td>
<td>1.00</td>
</tr>
<tr>
<td>Methotrexate</td>
<td>2 (2)</td>
<td>0 (0)</td>
<td>2 (3)</td>
<td>0.61</td>
</tr>
<tr>
<td>Hydroxychloroquine</td>
<td>2 (2)</td>
<td>1 (5)</td>
<td>1 (2)</td>
<td>0.45</td>
</tr>
<tr>
<td>Azathioprine</td>
<td>2 (2)</td>
<td>0 (0)</td>
<td>2 (3)</td>
<td>0.61</td>
</tr>
<tr>
<td>Infliximab</td>
<td>1 (1)</td>
<td>0 (0)</td>
<td>1 (2)</td>
<td>1.00</td>
</tr>
<tr>
<td>Current steroid use</td>
<td>53 (65)</td>
<td>17 (81)</td>
<td>36 (60)</td>
<td>0.11</td>
</tr>
<tr>
<td>Cardiac symptoms, n (%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>None</td>
<td>64 (79)</td>
<td>14 (67)</td>
<td>50 (83)</td>
<td>0.11</td>
</tr>
<tr>
<td>Syncope</td>
<td>2 (2)</td>
<td>2 (10)</td>
<td>0 (0)</td>
<td>0.06</td>
</tr>
<tr>
<td>Palpitations</td>
<td>6 (7)</td>
<td>1 (5)</td>
<td>5 (8)</td>
<td>0.68</td>
</tr>
<tr>
<td>Chest pain</td>
<td>5 (6)</td>
<td>1 (5)</td>
<td>4 (7)</td>
<td>1.00</td>
</tr>
<tr>
<td>Functional class</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>No limitations</td>
<td>77 (95)</td>
<td>18 (86)</td>
<td>59 (98)</td>
<td>0.06</td>
</tr>
<tr>
<td>NYHA class I–II</td>
<td>3 (4)</td>
<td>2 (10)</td>
<td>1 (2)</td>
<td></td>
</tr>
<tr>
<td>NYHA class III</td>
<td>1 (1)</td>
<td>1 (5)</td>
<td>0 (0)</td>
<td></td>
</tr>
</tbody>
</table>

### Table. Continued

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Overall (n=81)</th>
<th>DE-CMR+ (n=21)</th>
<th>DE-CMR− (n=60)</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>Twelve-lead ECG, n (%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Grade I atrioventricular block</td>
<td>3 (4)</td>
<td>1 (5)</td>
<td>2 (3)</td>
<td>0.15</td>
</tr>
<tr>
<td>Grade II or III atrioventricular block</td>
<td>0 (0)</td>
<td>...</td>
<td>...</td>
<td>...</td>
</tr>
<tr>
<td>Left bundle-branch block</td>
<td>1 (1)</td>
<td>1 (5)</td>
<td>0 (0)</td>
<td>1.00</td>
</tr>
<tr>
<td>Right bundle-branch block</td>
<td>4 (5)</td>
<td>2 (10)</td>
<td>2 (3)</td>
<td>0.26</td>
</tr>
<tr>
<td>Q wave</td>
<td>4 (5)</td>
<td>3 (14)</td>
<td>1 (2)</td>
<td>0.053</td>
</tr>
<tr>
<td>JMH criteria positive for cardiac sarcoidosis</td>
<td>10 (12)</td>
<td>8 (38)</td>
<td>2 (3)</td>
<td>0.002</td>
</tr>
</tbody>
</table>

NYHA indicates New York Heart Association.

### Cardiac Involvement by DE-CMR and JMH Criteria

CMR examinations were completed in all 81 patients, and all scans were included in the analysis. For evaluation of JMH status, a total of 133 non-CMR cardiac imaging studies were completed, representing an average of 1.6 studies per patient (echocardiography, n=81; radionuclide scintigraphy, n=18; cardiac catheterization, n=34). Ambulatory ECG was performed in few patients (n=8) and did not result in change in JMH status compared with 12-lead ECG alone. Hypерenhancement consistent with myocardial damage was identified in 21 patients (26%) by DE-CMR. Typical images are shown in Figure 2. JMH criteria identified cardiac involvement in 10 patients (12%), of whom 8 were also positive by DE-CMR. The rate of cardiac involvement by DE-CMR was >2-fold higher than by JMH status (P=0.005). Of the baseline clinical features in the Table, only JMH status was predictive of the presence of hyperenhancement in either univariable or multivariable logistic regression analysis (P=0.002).

### Hyperenhancement Characteristics

In patients with hyperenhancement, a median of 6.1% of the LV myocardium (2.3%, 19.0%) was involved. On a regional basis, 70% (79/113) of affected segments had nontransmural involvement (<50% hyperenhanced). The location of hyperenhancement was variable (collectively, none of the 17 myocardial segments were spared from involvement); however, there was a predilection for the basal and/or midventricular septum. This region was involved in 76% of affected patients (16/21). Relative to the pattern of involvement, 48% of hyperenhanced regions were classified as CAD type and 52% as non-CAD type. On a patient basis, 86% of affected patients (18/21) had at least 1 region with hyperenhancement in a non-CAD–type pattern. Examples of patients with various hyperenhancement patterns are shown in Figure 2. A
relatively common non-CAD–type pattern occurring in 67%
of DE-CMR–positive patients was subendocardial hyperen-
hancement of the RV side of the interventricular septum;however, only rarely was this widespread, and usually only 1
or 2 of the 5 septal segments were involved. In 4 patients (all
of whom also had LV hyperenhancement), hyperenhance-
ment of the RV free wall was observed. In all 4, the RV
outflow tract and/or anterobasal region of the RV was
involved. All 21 patients with hyperenhancement underwent
x-ray coronary angiography; none had evidence of obstruc-
tive coronary disease.

During the follow-up period, patients with hyperenhance-
ment were contacted for a repeat DE-CMR scan to evaluate
the persistence of hyperenhancement. However, 7 had inter-
val placement of a cardiac pacemaker or defibrillator, 4 died,
and 4 declined. The remaining 6 patients had a follow-up scan
8.3 \pm 5 months after the initial scan. Analysis of follow-up
images revealed the following: (1) All hyperenhanced regions
identified on the baseline scan were visible on the repeat scan
in the same myocardial locations (Figure 2); (2) no new areas
of hyperenhancement were observed; and (3) planimetry
demonstrated that the spatial extent of hyperenhancement
was unchanged (baseline, 8.7 \pm 2.7% versus follow-up,
8.4 \pm 2.4% of LV myocardium; \(P = 0.84\)).

LV Function and Volume
Overall, the median LVEF by cine-CMR was 56% (48%,
61%). LVEF was lower in DE-CMR–positive compared with
DE-CMR–negative patients (median, 45% versus 57%;
\(P < 0.0001\)); however, 29% of DE-CMR–positive patients had
LVEF \(> 50\). The median LV end-diastolic volume was 101
mL (89 mL, 137 mL) and was similar in DE-CMR–positive
compared with DE-CMR–negative patients (\(P = 0.41\)). Like-
wise, the extent of hyperenhancement by DE-CMR was
 correlates with LVEF (\(R = -0.54, P < 0.001\)) but only weakly
with LV end-diastolic volume (\(R = 0.20, P = 0.08\)).

Cardiac Pathology
Tissue was obtained for pathology evaluation in 15 patients
(19%), 13 by endomyocardial biopsy and 2 at autopsy. Figure 3
demonstrates the concordance between antemortem findings
by DE-CMR with postmortem pathology in 1 of the autopsy
patients. Figure 4 outlines the results in all 15 patients with
cardiac pathology in comparison to DE-CMR findings. Of the
4 patients who were positive for cardiac sarcoidosis by
pathology, DE-CMR demonstrated hyperenhancement in all
4 (100%), whereas JMH status was positive in 2 (50%). Of
the 11 patients who were negative for cardiac sarcoidosis by
pathology, DE-CMR was positive for cardiac involvement in
6 (55%); and JMH status was positive in 4 (36%). Import-
antly, in all 6 patients with discordant findings between
pathology and DE-CMR, tissue was obtained only by endo-
myocardial biopsy of the RV side of the interventricular
septum, and none had widespread hyperenhancement of the
RV side of the interventricular septum (involvement of \(> 3\) of
the 5 septal segments). Specifically, in 2 patients, the inter-
ventricular septum was completely free of hyperenhance-
ment; in 1 patient, a single segment was involved; in 2 patients, 2 segments were involved; and in 1 patient, 3 segments were involved.

Major Adverse Events
During a mean follow-up duration of 21±8 months, 8 patients had major adverse events: 6 died, 2 had ventricular tachyarrhythmia leading to defibrillator discharge (confirmed by stored electrograms; 1 patient also died later), and 1 developed atrioventricular block leading to pacemaker placement. Of the 6 deaths, 5 were cardiac, and 1 was from pulmonary complications. The events according to DE-CMR and JMH status are shown in Figure 5A. Of the 2 patients without cardiac involvement by DE-CMR who had adverse events (1 cardiac and 1 noncardiac death), both were also JMH negative. Kaplan–Meier survival curves are shown in Figure 5B. In DE-CMR–positive patients, the event rate and cardiac death rate were 9-fold and 11.5-fold higher, respectively, than in DE-CMR–negative patients (adverse events, 17.2% versus 1.9% per year; cardiac death, 11.5% versus 1.0% per year). In JMH-positive patients, the event rate and cardiac death rate were 3.5-fold and 3.9-fold higher, respectively, than in JMH-negative patients (adverse events, 14.5% versus 4.1% per year; cardiac death, 9.7% versus 2.5% per year). Given the few events, statistical comparisons between survival curves were not performed.

Discussion
In this study of consecutive patients with biopsy-proven extracardiac sarcoidosis who were prospectively screened for cardiac involvement, the principal finding was that DE-CMR identified myocardial abnormalities in significantly more patients than a standard clinical evaluation based on the consensus guidelines from the JMH (26% versus 12%). An

![Figure 4. Summary of cardiac pathology evaluation. Cardiac sarcoidosis was diagnosed by pathology evaluation in 4 patients. All 4 had cardiac involvement by DE-CMR. Of the 2 patients with positive endomyocardial biopsy, both had widespread hyperenhancement of the RV side of the interventricular septum (involvement of all 5 septal segments; example, patient G). Conversely, of 11 patients with negative endomyocardial biopsy, 6 had cardiac involvement by DE-CMR. These 6 had no or limited involvement of the RV side of the interventricular septum (example, patient H). See text for further details.]

![Figure 5. Events according to DE-CMR and JMH status. A, Adverse events according to DE-CMR and JMH status. Kaplan–Meier curves in B demonstrate that event-free survival and cardiac survival were reduced in patients positive for cardiac involvement by DE-CMR. See text for further details.]

Downloaded from http://circ.ahajournals.org/ by guest on July 25, 2017
additional finding was that DE-CMR–positive patients had a higher rate of adverse events, including cardiac death during follow-up, compared with DE-CMR–negative patients; however, the cohort was small, and there were few events.

The prevalence of cardiac sarcoidosis of 26% found by DE-CMR is consistent with autopsy series in the United States, which have found myocardial lesions in 20% to 27% of patients with sarcoidosis. For many reasons, the lower detection rate from the standard assessment is not surprising. As a first step in the diagnosis of cardiac sarcoidosis, JMH guidelines require an abnormal ECG, yet even in patients with findings of extensive myocardial infiltration on autopsy, the premortem ECG may be normal in 25%. More importantly, necropsy studies have demonstrated that many sarcoid patients suffering sudden death have only limited cardiac involvement, with lesions that are small and patchy.

Premortem, it is unlikely that these lesions would have been associated with gross changes in ventricular cavity size or function or detected by traditional cardiac imaging techniques. In the present study, the median extent of damage detected by DE-CMR was only 6.1% of myocardial mass. Additionally, on a regional basis, the majority of affected segments (70%) had nontransmural involvement (<50% hyperenhanced). The latter is important because nontransmural scarring, even if overall scar size is considerable, is frequently associated with normal ventricular wall motion and normal myocardial perfusion by nuclear scintigraphy. Thus, the ability of DE-CMR to detect small and/or nontransmural myocardial damage is likely the reason why a 2-fold higher rate of cardiac disease was identified compared with the standard assessment.

Improved diagnostic sensitivity may come at the cost of lower specificity. On this point, we note that none of the abnormalities detected by cardiac imaging, either as part of the JMH guidelines or from DE-CMR, are specific for cardiac sarcoidosis. For instance, any cardiomyopathic process may meet the JMH guidelines or from DE-CMR, are specific for cardiac sarcoidosis. For instance, any cardiomyopathic process may meet the JMH criteria of abnormal wall motion. Similarly, hyperenhancement on DE-CMR, representing scar tissue and/or necrosis, may result from a variety of causes, including ischemic heart disease. To account for this, as part of the study design, we excluded patients with prior myocardial infarction or known coronary disease. Furthermore, all patients with hyperenhancement underwent coronary angiography, and none had evidence of obstructive coronary disease. As a consequence, in our study population of patients with biopsy-proven sarcoidosis, it is highly likely that hyperenhancement represents cardiac sarcoidosis rather than another nonischemic process (eg, cardiac amyloidosis) because it is improbable that patients would be afflicted concurrently with 2 rare disorders.

Our pathology data are also consistent with the interpretation that hyperenhancement in the study population represents cardiac sarcoidosis. Of the 4 patients with pathology-confirmed cardiac sarcoid (2 at autopsy, 2 by endomyocardial biopsy), all 4 were identified by DE-CMR, whereas the standard assessment identified only 2. Moreover, in the 2 with autopsy, gross examination of the heart demonstrated a nearly 1-to-1 concordance between the location, shape, and extent of myocardial lesions and in vivo hyperenhancement (Figure 3). Interestingly, of the 13 patients undergoing endomyocardial biopsy, only 2 were positive for cardiac sarcoidosis. This diagnostic yield of 15% is similar to that found by Uemura et al who reported a positive biopsy rate of only 19% in a study cohort in whom the clinical diagnosis of cardiac sarcoidosis had already been made. Importantly, Uemura et al concluded that patients with clinical evidence of cardiac involvement be treated for cardiac sarcoidosis despite negative myocardial biopsies because inhomogeneous myocardial involvement and sampling error will frequently lead to false-negative biopsies. Our results suggest that 6 of 11 patients had false-negative biopsies (Figure 3), and the DE-CMR images indicate a mechanism: None of the 6 had widespread hyperenhancement of the RV side of the interventricular septum, which was the source of tissue for endomyocardial biopsy.

These findings suggest that DE-CMR provides additional value to standard assessment for the diagnosis of cardiac sarcoidosis and bolster similar conclusions from prior investigations. However, from a clinical care standpoint, the prognostic implications may be the most important. In this regard, the present study suggests that damage detected by DE-CMR may be associated with future adverse clinical events in patients with sarcoidosis. Even if small, regions of myocardial damage identified by DE-CMR may provide substrate for ventricular arrhythmias and conduction disturbances, and DE-CMR has shown prognostic utility independent of common clinical and functional predictors in other cardiac disorders. Nonetheless, in the present study, events were few, and caution should be used in interpreting these results until they are confirmed in a larger cohort.

The present report appears to be the first to prospectively demonstrate a link between a noninvasive index of cardiac involvement and clinical outcome in patients with sarcoidosis. Yazaki et al retrospectively identified 75 Japanese patients with the clinical diagnosis of cardiac sarcoidosis. Multivariable analysis demonstrated that LV enlargement by echocardiography, sustained ventricular tachycardia, and New York Heart Association functional class were independent predictors of all-cause mortality. Notably, in this cohort many patients had heart failure symptoms, and New York Heart Association functional class was the most powerful prognostic predictor. Smedema et al reviewed data in 101 consecutive patients with pulmonary sarcoidosis assessed at 2 university medical centers in the Netherlands. Although a battery of tests, including CMR, was performed in many patients, and during a mean follow-up of 1.7 years there were 4 deaths and 9 received a pacemaker and/or implantable cardioverter-defibrillator, the study was primarily descriptive, and there were no data relating results of noninvasive testing with clinical outcome. Additionally, it appears that only a minority of patients underwent inversion-recovery DE-CMR on the basis of another report the same year involving many of the same patients. In most patients, CMR images were acquired with the use of an older spin-echo sequence, and this is important because there are considerable differences in image quality between these techniques. Recently, Mehta et al reported on a prospective evaluation of 62 ambulatory patients with biopsy-proven extracardiac sarcoidosis who...
were screened for cardiac involvement. With the use of a structured algorithm, 26 patients underwent CMR, and 25 had positron emission tomography. On the basis of abnormalities found on either CMR or positron emission tomography, 24 patients (39%) were given the diagnosis of cardiac sarcoidosis. Over a mean follow-up of 1.8 years, no patient died or had ventricular arrhythmias, and the authors concluded that sarcoidal lesions seen on CMR or positron emission tomography do not predict arrhythmias in patients with preserved cardiac function. At first glance, this report appears to contrast with the present investigation. However, we note that hyperenhancement on DE-CMR was found in only 8 patients, and the chance of a type II error seems high. Conversely, in patients with negative DE-CMR scans, the results of this report appear to corroborate our finding of a low event rate (<2% per year) and a benign course.

Our study has a number of limitations. If patients systematically had ambulatory ECG in addition to the resting 12-lead ECG and had undergone every non-CMR cardiac imaging procedure, the number of patients with cardiac involvement by JMH criteria would likely have been higher. However, we attempted to compare DE-CMR with a clinically plausible approach (an average of 1.6 non-CMR imaging studies were performed per patient), and we note that an earlier investigation utilizing both resting and ambulatory ECG and multiple non-CMR imaging modalities demonstrated findings similar to the present study, namely, that DE-CMR was more sensitive for cardiac involvement than standard clinical approaches. T2-weighted sequences aimed at detecting acute edema/inflammation were not performed, and there may be some uncertainty on the precise pathophysiological interpretation of myocardial hyperenhancement. However, in our study cohort, nearly all patients had chronic sarcoidosis (median of 7 years since diagnosis), and none had acute cardiac symptoms. Moreover, repeat DE-CMR in a subset of patients demonstrated that the location, shape, and extent of hyperenhancement were unchanged (Figure 2). Along with the pathology findings, these suggest that hyperenhancement represents scar and/or chronic granulomatous tissue rather than acute necrosis with inflammation in our population. There appear to be racial differences in both the prevalence of cardiac sarcoidosis and its morbidity and mortality. Most of our patients were black, and caution should be used in extrapolating our findings to other patient populations. Although we believe that our study represents the largest experience with contemporary DE-CMR in patients with sarcoidosis to date, the cohort was relatively small and was from a single center, and clinical events were few. Our findings will need to be replicated in a larger, preferably multicenter investigation.

The presence of severe LV dysfunction (LVEF ≤30% to 40%) is often a key indication for clinical management decisions including implantable cardioverter-defibrillator therapy. However, in our study, only 2 of the 8 patients with adverse events during follow-up had an LVEF <40%. These data suggest that in patients with sarcoidosis, as in other populations, there may be a paradox in that although low LVEF identifies a group with relatively high risk, the majority of adverse events occur in patients with preserved LVEF. Because DE-CMR detected 6 of 8 patients with adverse events in the present study, future investigations could focus on whether DE-CMR can improve the management of patients with sarcoidosis, including the early diagnosis of cardiac involvement and the potential for prophylactic defibrillator use.

 Sources of Funding

Funding for the research was provided in part by National Institutes of Health grants RO1-HL64726 (R.J.K.) and RO1-HL63268 (R.M.J.) and the Joseph C. Greenfield Scholar Fund (M.R.P.).

 Disclosures

Drs Kim and Judd are inventors of a US patent on Delayed Enhancement magnetic resonance imaging, which is owned by Northwestern University. There are no other conflicts of interest or financial relationships to disclose.

 References

2. Longcope WT, Freeman DG. A study of sarcoidosis; based on a combined earlier investigation utilizing 160 cases including 30 autopsies from The Johns Hopkins Hospital and Massachusetts General Hospital. Medicine. 1952; 31:1–132.
In patients with sarcoidosis, sudden death is a leading cause of mortality, which may represent clinically unrecognized cardiac involvement. Delayed-enhancement cardiovascular magnetic resonance (DE-CMR) can detect very small amounts of myocardial damage; therefore, we sought to evaluate the usefulness of DE-CMR for identifying cardiac involvement in 81 consecutive patients with biopsy-proven extracardiac sarcoidosis. When compared with a standard clinical evaluation, which included 12-lead ECG and at least 1 dedicated non-CMR cardiac study (echocardiography, radionuclide myocardial perfusion imaging), DE-CMR identified cardiac involvement at a 2-fold higher rate. Patients were also followed up for 21 months on average for major adverse events (death, defibrillator shock, or pacemaker requirement). During follow-up, patients with myocardial damage on DE-CMR had a 9-fold higher rate of adverse events and an 11.5-fold higher rate of cardiac death than patients without damage. On the basis of these findings, we believe that DE-CMR is more than twice as sensitive for cardiac involvement as currently used standard methods. Myocardial damage detected by DE-CMR also appears to be associated with future adverse events, including cardiac death, but events were few, and this needs confirmation in a larger cohort.

**CLINICAL PERSPECTIVE**

In patients with sarcoidosis, sudden death is a leading cause of mortality, which may represent clinically unrecognized cardiac involvement. Delayed-enhancement cardiovascular magnetic resonance (DE-CMR) can detect very small amounts of myocardial damage; therefore, we sought to evaluate the usefulness of DE-CMR for identifying cardiac involvement in 81 consecutive patients with biopsy-proven extracardiac sarcoidosis. When compared with a standard clinical evaluation, which included 12-lead ECG and at least 1 dedicated non-CMR cardiac study (echocardiography, radionuclide perfusion imaging, or cardiac catheterization), DE-CMR identified cardiac involvement at a 2-fold higher rate. Patients were also followed up for 21 months on average for major adverse events (death, defibrillator shock, or pacemaker requirement). During follow-up, patients with myocardial damage on DE-CMR had a 9-fold higher rate of adverse events and an 11.5-fold higher rate of cardiac death than patients without damage. On the basis of these findings, we believe that DE-CMR is more than twice as sensitive for cardiac involvement as currently used standard methods. Myocardial damage detected by DE-CMR also appears to be associated with future adverse events, including cardiac death, but events were few, and this needs confirmation in a larger cohort.
Detection of Myocardial Damage in Patients With Sarcoidosis

_Circulation._ 2009;120:1969-1977; originally published online November 2, 2009; doi: 10.1161/CIRCULATIONAHA.109.851352
_Circulation_ is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2009 American Heart Association, Inc. All rights reserved.
Print ISSN: 0009-7322. Online ISSN: 1524-4539

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://circ.ahajournals.org/content/120/20/1969

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in _Circulation_ can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to _Circulation_ is online at:
http://circ.ahajournals.org//subscriptions/